{"id":"tp-41172","type":"article-newspaper","title":"Johnson & Johnson's JNJ-6143 Shows 75% Response Rate in Early Trial","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/41172","datePublished":"2026-10-26T17:25:14.000Z","dateModified":"2026-10-26T17:25:14.000Z","language":"en","abstract":"The oral RIPTAC small molecule was previously known as HLD-0915.","section":"Business","references":[]}